- Published
- 01 January 2021
- Letter
Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes
- Authors
- Source
- Diabetic Medicine
Full text
Abstract
The RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial found that dexamethasone 6 mg once per day for 10 days reduced deaths by one-third in ventilated patients and by one-fifth in other patients, receiving oxygen therapy. This equates to the prevention of one death in around eight ventilated patients, or one in around 25 patients requiring oxygen.
Rights
This content is not covered by the Open Government Licence. Please see source record or item for information on rights and permissions.
Cite as
Rayman, G., Lumb, A., Kennon, B., Cottrell, C., Nagi, D., Page, E., Voigt, D., Courtney, H., Atkins, H., Platts, J., Higgins, K., Dhatariya, K., Patel, M., Narendran, P., Kar, P., Newland-Jones, P., Stewart, R., Burr, O. & Thomas, S. 2021, 'Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes', Diabetic Medicine, 38 (1), article no: e14378 . https://doi.org/10.1111/dme.14378